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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a common disease, associated with cardiovascular
disease. Many patients use (long-acting) bronchodilators, whilst they continue smoking alongside. We hypothesised
an interaction between bronchodilators and smoking that enhances smoke exposure, and hence cardiovascular
disease. In this paper, we report our study protocol that explores the fundamental interaction, i.e. smoke retention.
Method: The design consists of a double-blinded, placebo-controlled, randomised crossover trial, in which 40
COPD patients smoke cigarettes during both undilated and maximal bronchodilated conditions. Our primary
outcome is the retention of cigarette smoke, expressed as tar and nicotine weight. The inhaled tar weights are
calculated from the correlated extracted nicotine weights in cigarette filters, whereas the exhaled weights are
collected on Cambridge filters. We established the inhaled weight calculations by a pilot study, that included
paired measurements from several smoking regimes. Our study protocol is approved by the local accredited
medical review ethics committee.
Discussion: Our study is currently in progress. The pilot study revealed valid equations for inhaled tar and nicotine,
with an R2 of 0.82 and 0.74 (p < 0.01), respectively. We developed a method to study pulmonary smoke retentions
in COPD patients under the influence of bronchodilation which may affect smoking-related disease. This trial will
provide fundamental knowledge about the (cardiovascular) safety of bronchodilators in patients with COPD who
persist in their habit of cigarette smoking.
Trial registration: ClinicalTrials.gov: NCT00981851
Background
Chronic obstructive pulmonary disease (COPD) is a
common chronic disease, characterised by poorly rever-
sible and progressive airflow obstruction. A substantial
fraction of COPD-related mortality and morbidity is due
to cardiovascular disease [1-3]. Both diseases share an
important risk factor: smoking. Cigarette smoking
causes over 80% of COPD, whereas 20% of cardiovascu-
lar mortality is attributable to smoking [4,3,5,6]. Cessa-
tion of cigarette smoking is an important prognostic
factor in patients with COPD and cardiovascular disease.
Besides, smoking cessation is essential in preventing
development of cardiovascular disease in all people,
including COPD patients. However, half of COPD
patients are persistent smokers [7,4,8,9,5].
Meanwhile, the cornerstone of pharmaceutical treat-
ment of COPD symptoms is bronchodilation. It seems
rational however, that bronchodilation diminishes the
hyperinflated state of the lung, enhances deeper smoke
inhalation and as a result increases the pulmonary
deposition or uptake of pathogenic cigarette smoke con-
stituents. Concurrently, the amount of cigarettes
smoked - i.e. the amount of smoke - is related positively
to cardiac mortality [4,5,10]. Therefore, we hypothesised
a hazardous interaction between chronic bronchodilation
and smoking, that would result in increased cardiovascu-
lar morbidity and mortality in COPD patients who perse-
vere in smoking [11]. If the hypothesized interaction does
indeed exist, the consequences in terms of pharma-
cotherapeutic management of patients with COPD would
* Correspondence: w.vandijk@aios.umcn.nl
1Department of Primary and Community Care, Radboud University Nijmegen
Medical Centre
Full list of author information is available at the end of the article
van Dijk et al. Trials 2011, 12:37
http://www.trialsjournal.com/content/12/1/37 TRIALS
© 2011 van Dijk et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
be substantial. However, no strong evidence to substanti-
ate our hypothesis has been published yet. With the ran-
domised controlled trial described in this paper we aim
to expose the fundamental mechanism of interaction.
Similar studies on smoke retention in general have been
reported, but not in relation to bronchodilator treatment
or in patients with COPD [12-15].
Our first objective is essentially to demonstrate a
proof of concept of the fundamental underlying assump-
tion: does administration of a bronchodilator to a
patient with COPD lead to increased retention of cigar-
ette smoke constituents. In this article we describe the
design and methods of our study that determines the
effect of bronchodilation on smoke retention in COPD
patients when they smoke a cigarette. In addition, we
determine the effect of bronchodilation on smoking pat-
terns and short-term biological effects associated with
cardiovascular disease. Apart from our methods, we
report the results of our pilot study that validated the
retention measurements.
Method
Interaction in COPD experiment (ICE) is a randomised
trial designed to evaluate the effect of bronchodilators
on smoke retention in COPD patients.
Study design
The study is designed as a double-blinded, placebo-con-
trolled, randomised crossover trial, in which 40 COPD
patients - who are current smokers - smoke a cigarette
under controlled conditions, both during undilated and
maximal bronchodilated conditions during two separate
sessions. Participants have a ‘wash-out’ period of 1 week
between both sessions and the experiment always initi-
ates between 8:00 and 9:00 AM. The study is registered
at http://www.clinicaltrials.gov identification number
NCT00981851.
Interventions
After inclusion, patients are randomly allocated to com-
mence with one of both bronchodilated conditions. Dur-
ing one session, participants smoke a first cigarette, have
their medication administered directly after, and
45 minutes later they smoke their second cigarette.
• Bronchodilation. To accomplish both bronchodi-
lated conditions, patients receive either a combina-
tion of potent bronchodilating drugs - 5 μg
tiotropiumbromide dry powder inhalation by Respi-
mat as well as 400 μg aerosolized salbutamol by
volume spacer - or a combination of their placebos.
These bronchodilators ensure a gradual and maximal
bronchodilation after 45 minutes and both offer
similar placebos [16,17]. In order to initiate the
experiment undilated, patients have to refrain from
bronchodilators according to table 1. Patients are
allowed short-acting bronchodilators up to 8 hours
before the experiment to minimise bronchodilator
withdrawal. To minimise intra-individual variation in
baseline bronchoconstriction, patients should not
have had an exacerbation or have used more than
usual short-acting rescue medication within the pre-
vious week.
• Smoking. Smoking occurs according to well con-
trolled protocols. To neutralise the effect on smok-
ing patterns by nicotine craving, tobacco smoking is
accepted up to 8 hours before the experiment and
patients have a cigarette prior to medication admin-
istration. During all study sessions patients smoke
CM6 cigarettes, a non-commercial cigarette with
relatively little variation in smoke yields [18]. Cigar-
ettes are conditioned at 22°C and at 60% relative
humidity - according to ISO standards - in an incu-
bator with a saturated mixed salt solution [19].
Cigarettes are ignited electrically. Participants wear a
nose-clip, and are instructed to inhale all smoke,
exhale into a mouthpiece connected to Cambridge
filters and to smoke the cigarettes up to a marking
spot 32 mm from the tipping end. Cigarettes are
extinguished by pulling off the burning core to pre-
serve the cigarette filter.
The interventions are executed at a laboratory loca-
tion, separated from patient care, specifically facilitated
to avoid smoke exposure of researchers and department
personnel. The local authorised university safety-board
and housing-board approved this facility in accordance
to national and local smoking legislation.
Eligibility
Patients are selectively recruited as from October 2009
by their own respiratory consultant or respiratory nurse
during regular scheduled clinic visits, at the pulmonary
diseases department of the Radboud University Nijme-
gen Medical Centre. Eligible candidates are initially
selected from pulmonary patient files, based on the
selection criteria (table 2). We recruit patients with
COPD (defined according to current GOLD criteria), [3]
without interfering co-morbidities, who are current
Table 1 Duration of bronchodilator abstinence
Abstinence (hours) Bronchodilator
• 8 • Salbutamol
• Terbutaline
• Ipratropium bromide
• 24 • Formoterol
• Salmeterol
• 48 • Tiotropium bromide
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smokers, and who are capable of fulfilling the experi-
ment physically and logistically. Patients with interfering
factors such as asthmatic features or other interfering
non-COPD respiratory disorders are excluded.
Candidates receive written information and have at
least one week to consider their participation. The
investigator (WvD) contacts candidates by telephone to
address further questions and to provide additional
information if necessary. Participants sign an informed
consent form. The encoded identities are only accessible
by the investigator and research assistant. The local
accredited medical review ethics committee approved
our protocol: CMO region Arnhem-Nijmegen, CMO
2009/037. We explicitly support the quit-smoking advice
and do not interfere if a patient has initiated an attempt
to quit smoking.
Blinding
Placebo and bronchodilator administrations are double-
blinded. Blinding is only known to a research nurse,
who prepares and delivers the medication for each study
participant, and does not have any other involvement.
The placebos are not distinguishable from the broncho-
dilating drugs through appearance or administration.
Pulmonary function tests after drug administration are
not performed until the final cigarette has been smoked.
We will unblind all study medication simultaneously
after the final participant has concluded the experiment
or individually in case of a serious adverse event.
Sample size calculation
In a cross-over design with paired samples, a number of
34 patients is sufficient to demonstrate a medium stan-
dardised effect size (δ = 0.5) of pre and post mean differ-
ence between the two different conditions (assumptions:
a = 0.05, 1-b = 0.80, two-tailed testing, c = 7.9): n = c/δ2
+ 2 [20]. The medium standardised effect size is derived
from an interpretation of Feng’s study about retention
dynamics [13]. We base the increase in tar retention on
the assumption that our participants execute an average
smoking pattern, that bronchodilation results in a 20%
increase of Forced Vital Capacitiy (FVC), and that this
increase results in 20% more as well as deeper smoke
inhalation [9]. Figure 1 shows our interpretation of
Feng’s study and reveals a subsequent estimated 5%
Table 2 Eligibility
Inclusion criteria Exclusion criteria
• COPD GOLD stage II-III (i.e.
FEV1/FVC <0.70 and FEV1 30-80%
of predicted value).
• Current cigarette smoking.
• Willing to provide written
informed consent.
• Willing to refrain from smoking
and avoid use of a bronchodilator
>8 hours.
• Registered in one of the
recruitment institutes.
• COPD GOLD stage I or IV.
• Active asthmatic component:
present asthma by complaints,
positive histamine provocation
test, eosinofilia or reversibility
≥ 10% of predicted.
• Unable to perform the whole
experiment physically or due to
communication problems.
• Recent, active and relevant
non-COPD respiratory disorders.
Figure 1 20% increase (—) of a normal inhalation volume (–) leads to a mean 5% increase in retention (*) of 3 main tar compounds.
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increase in tar retention caused by bronchodilation. The
mean standard deviation of tar retention approximates
10%, based on three main tar substances, and results in
an effect size of 0.5 (increase/standard deviation) [13].
Outcome measures
Primary outcome will be the evaluation for both
bronchodilated conditions of changes in cigarette smoke
retention between before and after medication adminis-
tration. These retentions are calculated by both the
inhaled tar and nicotine weights (mg) minus their
exhaled amount, divided by the inhaled amount [13].
Secondary outcomes include smoking patterns - pre-
sented by mean inhalation as well as exhalation volume
(ml) and time (seconds) - and respiratory function by
Forced Expiratory Volume in the first second (FEV1)
and FVC. These variables will also be analysed for their
correlation with smoke retention. Another secondary
outcome is the short-term reaction of biomarkers asso-
ciated with cardiovascular disease in long-term studies,
i.e. C-reactive protein and platelet activation by fibrino-
gen [21-23]. Study outcomes are presented in table 3.
Measurements
Pilot study
Tar and nicotine yields are related to the amount of nico-
tine in cigarette filters [13,15]. We performed a pilot study
at the Food and Consumer Product Safety Authority,
Eindhoven, the Netherlands (FCA) to determine these
relations for CM6 cigarettes, when artificially smoked up
to 32 mm from the tipping end. A Cerulean SM450 smok-
ing machine performed smoking at 6 different smoking
regimes - ranging from 35 ml to 55 ml per 2-second puffs,
at 1 and 2 puffs per minute. After smoking, whole cigar-
ette filters were extracted in a 20 ml isopropanol-based
solution and analysed for their nicotine amounts by gas
chromatography, according to standardised operating pro-
cedures (ISO method 10315). For single cigarettes, tar was
captured on a paired Cambridge filter pad, which was
weighed before and after smoking to generate a gross tar
weight. Subsequently these filters were extracted and ana-
lysed similar to the cigarette filters for their nicotine
amount - i.e. nicotine yield - and water amounts. Subtract-
ing the water amount from the gross tar weight, corrected
by addition of the water amount of blank filter pads,
resulted in the net tar weight, i.e. tar yield (ISO method
4387). The paired values resulted in an equation to calcu-
late inhaled nicotine and tar amounts by cigarette filter
nicotine weights.
From our pilot study, we obtained 30 valid results of
paired CM6 cigarette filters and Cambridge filters, by 6
different smoking regimes, and generated two equations to
estimate the inhaled amounts of tar and nicotine for our
participants: nicotine inhalation (mg) = 1.4 * nicotine
(cigarette filter) + 0.35 (R2 = 0.82, p < 0.01, figure 2). Tar
inhalation (mg) = 20.8 * nicotine (cigarette filter) +
1.06 (R2 = 0.74, p < 0.01).
Baseline assessment
By questionnaire we attain medical history, smoking
history, all medication use, and - prior to both sessions -
recent use of cigarettes, bronchodilation and rescue med-
ication. FEV1 and FVC are measured each session by a
portable spirometer - Micro loop 36-ML3535MK8, Care-
fusion. A comprehensive baseline pulmonary function
test is by spirometry: Total Lung Capacity (TLC), Diffu-
sion and Inspiratory Vital Capacity (IVC). Participants
wear an inductive plethysmography garment - Vivo-
metrics Lifeshirt® - that measures single smoking puffs
real-time and facilitates smoking pattern analyses by
Vivologic software [13]. We calibrate the Lifeshirt® by 10
simultaneous spirometric mean tidal volume measure-
ments. We attain baseline biomarkers by venous blood
samples. Table 4 summarises all baseline characteristics.
Experiment
Each session, participants smoke two cigarettes while we
mark smoke inhalations manually for the Lifeshirt®. In
addition, these puffs will be visually identified during
the Lifeshirt data management. After smoking the sec-
ond cigarette, we measure FEV1 and FVC twice by
handheld spirometry to determine both airflow obstruc-
tion and reversibility. We repeat blood sampling from
the same vein twice as well. In order to establish inhaled
tar and nicotine weights, we analyse the cigarette filters
at the FCA for their nicotine contents. We establish
exhaled tar and nicotine weights by analyses of Cam-
bridge filters similar to the pilot study [12,13]. These
Cambridge filters capture approximately all tar. To
diminish losses, participants wear a nose clip, are
instructed to inhale all smoke, and exhale all smoke
through a mouthpiece, which connects to two parallel
55 mm Cambridge filters. We use inert PTFE (Teflon)
tubing, PTFE filter pad holders and metal connectors,
Table 3 Study outcomes
Outcome Variable
Primary outcome Smoke retention
• Tar (%)
• Nicotine (%)
Secondary outcomes Pulmonary function
• FEV1 reversibility (%)
• FVC reversibility (%)
Smoking pattern
• Mean inhalation time and volume (sec + ml)
• Mean exhalation time and volume (sec + ml)
• Total smoking time (min)
• Amount of puffs (n)
Biomarkers
• CRP and high sensitivity CRP (mg/l)
• Fibrinogen (mg/l)
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and maintained temperature at 40°C to prevent smoke
sedimentation and condensation and to prevent filter
pads from blocking. We reduced the dead space to
35 ml. Filter pads are re-weighed after smoking, only
after water evaporation has stabilised. All filters are
vacuum sealed and preserved at room temperature.
Prior to analyses at the FCA, filters are re-stabilised at
22°C at 60% relative humidity [13,14].
Statistical analysis
We use SPSS 16.0 to statistically analyse our results. We
compare medication induced changes in cigarette smoke
retention between the placebos and bronchodilators, by
mixed model analyses. Baseline characteristics are stu-
died as determinants of short-term changes in smoke
retention and cardiovascular biomarkers by univariate
analysis of variance (ANOVA). Pulmonary function and
smoking pattern are studied for a correlation with
smoke retention by a separate correlation analyses.
Regression analyses was used for our pilot study.
Discussion
The aim of our study is to demonstrate a fundamental
effect of bronchodilation on smoke retention as a proof
of concept for our hypothesis that suggests a hazardous
interactive effect of bronchodilation and smoking on
cardiovascular disease in COPD patients. The study
design is directed at selecting a population in which the
experiment is rather safe and where we expect some
bronchodilator effect on the FVC: COPD Gold classifi-
cation II-III. In addition, this group represents 70% of
COPD patients. We therefore believe, selection bias is
minimal and generalisability is reasonable [24].
The power of our study benefits from the crossover
design which reduces the required sample size. The
study effect is amplified by maximum bronchodilation
in one session - by combining a beta-2 agonist and
anticholinergic bronchodilator - and maintaining
Figure 2 Correlation between cigarette and Cambridge filter nicotine (Pearson’s correlation coefficient of 0.90).
Table 4 Baseline characteristics
Variables
History
• COPD GOLD-classification
• Pulmonary and other diseases
• Smoking
Medication
• Pulmonary medication
• Co-medication
Pulmonary function
• FEV1 pre- and post
bronchodilation
• FVC pre- and post bronchodilation
• Inspiratory Vital Capacity
• Total Lung Capacity
• Diffusion
Pre-experiment condition
check
• Last smoke
• Last bronchodilator use
• Rescue bronchodilator last
week?
• Exacerbation last week?
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maximum deprivation of bronchodilation in the other
session. Validity of the study is consolidated by the fol-
lowing: participants have a break of one week between
the first and second measurement session to eliminate
any carry-over effects. Sessions are scheduled at stan-
dardised times to decrease periodicity by cyclic day-
time influences [25]. Randomisation and blinding
throughout the experiment is guaranteed by indepen-
dent research assistants, undistinguishable placebos
and post medication pulmonary function tests after the
second cigarette only. The way patients for the study
are recruited and all other procedures used in the
study are conform ethical standards. Participants do
not have to smoke or take medication differently than
they are used to except for pre-experimental absti-
nence. We optimised exhaled tar and nicotine mea-
surements by heating of the construction to exclude
smoke condensation, inert materials and a small dead
space to avoid sedimentation, and clear instructions
and a nose clip to prevent smoke losses.
We measure inhalation and exhalation tar and nico-
tine amounts by a method similar to methods that
have been proven valid in previous studies [12-15]. To
minimise variation in inhaled amounts of tar and nico-
tine, we standardised the measurements by condition-
ing of the cigarettes, lighting them electrically, and
smoking them up to 32 mm from the tipping end. In
addition, by utilising just one cigarette brand, we are
able to exclude the variation of the brand-specific
nicotine filtration efficiency. A relatively suboptimal
correlation between cigarette filter nicotine and inhala-
tion amounts is likely due to the influence of different
smoking regimes, specifically puff volume. Still, we
assume our crossover-based method is valid since dif-
ferences in smoking regimes consist merely between
patients and not as much within patients. Furthermore,
daily differences in smoke patterns are accounted for
by similar nicotine deprivation for both conditions and
retention differences between before and after medica-
tion both sessions.
Conclusion
We believe we developed a valid method to study the
fundamental interaction between bronchodilation and
cigarette smoking in COPD patients that may result in
different pulmonary smoke retentions and parallel short-
term cardiovascular effects. The pilot study on individual
smoke yield measurements appears useful for future
smoke studies. Our method reduces sample size and the
individual burden by participation is limited. We expect
that our study will provide crucial new insights on the
safety of prescribing bronchodilators to patients with
COPD who persist in their habit of cigarette smoking.
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